Impact of Mass Drug Administration with Ivermectin, Diethylcarbamazine, and Albendazole in Elimination of Lymphatic Filariasis in Five Districts of Nepal
| dc.contributor.author | Mahato RK | |
| dc.contributor.author | Dahal G | |
| dc.contributor.author | Ghimire YC | |
| dc.contributor.author | Marasini RP | |
| dc.contributor.author | Hayman DTS | |
| dc.contributor.author | Krishnamoorthy K | |
| dc.contributor.author | Sharma SR | |
| dc.contributor.author | Sah D | |
| dc.contributor.author | Ray RB | |
| dc.contributor.author | Subedi R | |
| dc.contributor.author | Pandit KR | |
| dc.contributor.author | Khatiwada SR | |
| dc.contributor.author | Ojha AB | |
| dc.contributor.author | Mahaseth S | |
| dc.contributor.author | Mahata DB | |
| dc.contributor.author | Brady M | |
| dc.contributor.author | Burgert-Brucker C | |
| dc.contributor.author | Stone B | |
| dc.contributor.author | Parajuli A | |
| dc.contributor.author | Paudel SR | |
| dc.contributor.author | Devkota BP | |
| dc.contributor.author | Jha CB | |
| dc.contributor.author | Paudel KP | |
| dc.contributor.author | Sapkota BP | |
| dc.contributor.author | Bajracharya B | |
| dc.date.accessioned | 2026-03-24T22:37:26Z | |
| dc.date.issued | 2025-06-04 | |
| dc.identifier.doi | 10.1101/2025.06.03.25328869 | |
| dc.identifier.elements-type | preprint | |
| dc.identifier.uri | https://mro.massey.ac.nz/handle/10179/74369 | |
| dc.language | English | |
| dc.publisher.uri | https://www.medrxiv.org/content/10.1101/2025.06.03.25328869v1 | |
| dc.rights | (c) The author/s | en |
| dc.rights.license | CC BY 4.0 | en |
| dc.rights.uri | https://creativecommons.org/licenses/by/4.0/ | en |
| dc.title | Impact of Mass Drug Administration with Ivermectin, Diethylcarbamazine, and Albendazole in Elimination of Lymphatic Filariasis in Five Districts of Nepal | |
| dc.type | other | |
| pubs.elements-id | 610328 | |
| pubs.organisational-group | Other |
